MedTrace Logo

ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma

NCT04112238 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2022-03-22

No results posted yet for this study

Summary

The study is a prospective clinical study which investigates the use of new diagnostic methods to localize aggressive lymphoma involving the central nervous system(CNS). By measuring cell-free tumor DNA and metabolomics in cerebrospinal fluid and blood in patients with systemic Diffuse Large B-cell Lymphoma the investigators aim to improve the diagnostic certainty of an impending relapse of lymphoma in CNS.

Conditions

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Anne Elisabeth Reuben Tolley, MD · Herlev Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-29
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04112238 on ClinicalTrials.gov